Iovance Biotherapeutics, Inc.
IOVA
Updated: 25/09/2026, 10:09:26
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
No summaries found.
- Share price
- $10.80
- Market cap
- $4.82B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Frederick G. Vogt
- Employees
- 975
- IPO date
- 15/10/2010
- Beta
- 0.701
- Last dividend
- $0.00
- Day range
- $10.15 – $10.83
- 52-week range
- $1.76 – $10.98
- 1-day performance
- 5.99%
- 1-year performance
- 513.64%
- Current drawdown (1Y)
- -1.64%
- CIK
- 0001425205
- CUSIP
- 462260100
- ISIN
- US4622601007
- Created
- 07/12/2025, 04:45:02
- Last update
- 25/09/2026, 10:09:26
Track Iovance Biotherapeutics, Inc. with an AI analyst
See which prediction-market events move IOVA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
GlobeNewsWire • STOCK • 03/06/2026, 18:05:00
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
The Motley Fool • STOCK • 02/06/2026, 02:15:00
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Proactive Investors • STOCK • 01/06/2026, 14:32:25
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 22/05/2026, 19:15:00
Iovance Biotherapeutics to Present at Upcoming Conference
GlobeNewsWire • STOCK • 21/05/2026, 10:05:00
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Zacks Investment Research • STOCK • 08/05/2026, 14:11:09
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 19:21:16
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
GlobeNewsWire • STOCK • 07/05/2026, 09:05:00
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research • STOCK • 30/04/2026, 13:01:42
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
GlobeNewsWire • STOCK • 27/04/2026, 10:01:00
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 17/04/2026, 19:15:00
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Seeking Alpha • STOCK • 07/04/2026, 00:05:16